Jim Simons Syros Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.69 - $1.21 $269,064 - $471,838	-389,949 Reduced 47.62%	429,013 $413,000
Q1 2022 May 13, 2022	BUY	$1.02 - $3.8 $835,341 - $3.11 Million	818,962 New	818,962 $975,000
Q1 2021 May 13, 2021	SELL	$7.19 - $14.95 $623,373 - $1.3 Million	-86,700 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$6.66 - $14.66 $577,422 - $1.27 Million	86,700 New	86,700 $941,000
Q3 2020 Nov 13, 2020	SELL	$8.69 - $14.47 $506,627 - $843,601	-58,300 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.21 - $11.03 $303,743 - $643,049	58,300 New	58,300 $621,000
Q1 2020 May 14, 2020	SELL	$4.46 - $9.2 $575,719 - $1.19 Million	-129,085 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$4.52 - $10.1 $711,967 - $1.59 Million	-157,515 Reduced 54.96%	129,085 $892,000
Q3 2019 Nov 13, 2019	SELL	$7.14 - $11.65 $77,112 - $125,820	-10,800 Reduced 3.63%	286,600 $2.98 Million
Q2 2019 Aug 12, 2019	BUY	$5.5 - $9.75 $422,950 - $749,775	76,900 Added 34.88%	297,400 $2.75 Million
Q1 2019 May 14, 2019	BUY	$5.51 - $9.59 $527,858 - $918,722	95,800 Added 76.82%	220,500 $2.02 Million
Q4 2018 Feb 13, 2019	BUY	$5.55 - $11.34 $692,085 - $1.41 Million	124,700 New	124,700 $695,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.